Former Novartis drug for ultra-rare disease gets speedy FDA review
Three years after paying a modest $20 million upfront to grab a late-stage rare disease drug from Novartis, Pharming has lined up a priority review at the FDA.
Known at the time as CDZ173, leniolisib belongs to the PI3Kẟ (phosphoinositide 3-kinase delta) inhibitor class, which is best known for cancer applications. But Novartis took a different path, testing it for an immunodeficiency disease called activated phosphoinositide 3-kinase delta syndrome, or APDS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.